logo-loader

Investor Update: SkinBio signs commercial deal with chemical giant Croda

Headlines from the Proactive UK newsroom.

SkinBioTherapeutics (LON:SBTX) has signed a commercial and manufacturing agreement for its Skinbiotix technology with speciality chemical giant Croda.  It is the first major deal for the product with Croda to design and manufacture a new active skincare ingredient for its 12,000 cosmetic customers.

European Metals (LON:EMH) is to sell a majority stake in the Cinovec lithium project in the Czech Republic for €34mln. Local power utility CEZ is buying a 51% stake and will become the project’s strategic partner.

Falcon Oil & Gas Ltd (LON:FOG, CVE:FO) has told investors that it’s completed drilling the vertical section of the Kyalla 117 N2-1 appraisal well, in Australia’s Beetaloo basin.

Integumen (LON:SKIN) says a project in Ireland to test reservoir water for E.coli returned results with almost 100% accuracy in a matter of seconds. The Rinocloud AI platform tested samples from a fully autonomous data buoy at Inniscarra in Cork.

Kingfisher (LON:KGF) saw sales fall again due to problems with new ranges, reduced promotional activity, ongoing problems in France and a weak UK market.

Foreign exchange specialist Argentex (LON:AGFX) boosted half year revenue by 42% in its first results since listing. Underlying profits more than doubled to £6.5mln as uncertainty surrounding the general election and Brexit encouraged a rush of new corporate clients. 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 8 hours ago

RNS

Result of AGM

4 weeks, 2 days ago

Notice of AGM

on 26/11/19

Final Results

on 26/11/19

Commercial Agreement

on 20/11/19

2 min read